AGIO stock drops 50% on mixed mitapivat Phase 3

What pushed Agios shares lower

Agios Pharmaceuticals (NASDAQ: AGIO) saw a steep sell-off after reporting mixed topline results from the Phase 3 RISE UP trial of mitapivat in sickle cell disease (SCD). The company said the study met one primary endpoint for hemoglobin response, but failed to show a statistically significant improvement in annualized pain crises. Investors reacted by repricing the program’s regulatory and commercial prospects, as pain crises and fatigue are viewed as key outcomes for patients.

The drop also landed against a backdrop of heightened bearish positioning. Short interest stood at 6.6 million shares, representing 11.8% of the float, and was up 6.7% versus the previous reporting period.

RISE UP trial: what worked and what missed

Agios reported that mitapivat achieved a statistically significant improvement versus placebo on the primary endpoint tied to hemoglobin response. The company also cited positive effects on hemoglobin concentration and indirect bilirubin levels.

But the same readout missed on outcomes investors tend to weigh heavily for SCD therapies. The trial did not demonstrate a statistically significant reduction in sickle cell pain crises and also reported no improvement in fatigue, which is a key quality-of-life measure.

Safety and adverse event context investors focused on

Alongside efficacy, the trial’s safety profile drew attention in market commentary. Serious adverse events were reported in both the treatment and placebo groups. While that detail does not by itself establish a new safety signal, it added to uncertainty as investors assessed the overall risk-benefit profile.

How sharply did the stock react

The market reaction was immediate and severe. One report noted Agios’ stock plummeted by $12.33 to open at $13.16 after the trial update. In broader trading coverage, the shares were described as down roughly 45% in premarket trading and around 49% lower at the time of writing, marking a new 52-week low.

In another widely cited move, the stock was nearly halved, falling from about $15 to $14. In the session described as the company’s worst on record, the stock closed down 51% at $12.34 before edging up 0.9% in after-hours trading.

Short interest and days-to-cover: what positioning shows

Short interest in Agios Pharmaceuticals was reported at 6.6 million shares, up 6.7% from the prior period, and equal to 11.8% of the float. Over the past 12 months, short interest increased 67.9%, which points to a notable rise in bearish positioning.

Liquidity for shorts to cover, measured by days to cover, stood at 6.4 days, down 22.3% from the previous period. The ratio was described as volatile over time, ranging from 1.3 to 10.0 days. A 6.4 days-to-cover figure implies covering could take roughly about a week of average volume.

Regulatory path: FDA talks and accelerated approval plan

Agios indicated it plans to engage with the U.S. FDA in early 2026 and has said it intends to submit a marketing application in the first quarter of 2026 as it pursues potential U.S. approval for mitapivat in SCD.

Separately, a Goldman Sachs note referenced Agios’ plans to seek accelerated FDA approval for mitapivat in SCD following a pre-sNDA meeting. That note said a confirmatory trial protocol had been submitted and that the update was not expected to impact FY26 operating expenses (OpEx).

Analyst reaction: targets cut after the readout

Following the mixed Phase 3 readout, multiple firms reduced their price targets, citing a more uncertain regulatory path. Bank of America Securities lowered its price target to $12 from $14 while maintaining a Buy rating, pointing to what it called “only modest directional benefit” on pain crises and fatigue and a less certain regulatory and commercial path.

RBC Capital downgraded Agios to Sector Perform from Outperform and cut its target to $18 from $17, arguing the drug fell short on endpoints most important to patients and signaling reduced odds of success and uptake even if approved. H.C. Wainwright lowered its target to $18 from $16 and reiterated a Buy rating, calling the market reaction “overdone” while acknowledging increased uncertainty.

Goldman Sachs, in a separate development tied to regulatory planning, raised its price target to $12 from $18 and maintained a Neutral rating.

Financial snapshot and commercial context

Agios’ financial profile remains a key part of the risk debate. The company reported a loss of USD 413 million last year with USD 54 million in revenue. Another data point in the coverage cited revenue of USD 44.79 million with no growth over the past three years.

Mitapivat, sold as Pyrukynd for a rare form of anemia, was reported to have generated about USD 22 million in sales over the first nine months of the year. Separately, Agios said it filed for approval of the drug in thalassaemia and was hoping for a positive FDA verdict before the end of the year, while another report noted the agency delayed a decision in September and said a verdict was expected by Dec. 7.

Legal overhang: investigation announcement

Levi & Korsinsky announced it initiated an investigation into Agios Pharmaceuticals regarding potential violations of federal securities laws. Such announcements can increase headline risk and add to volatility, particularly when they coincide with large price moves.

Key figures at a glance

What investors will watch next

The next milestones in the coverage are regulatory-facing. Agios plans to discuss the program with the FDA in early 2026 and aims to submit a marketing application in the first quarter of 2026.

Investors will also track any follow-through from the accelerated approval strategy referenced after the pre-sNDA meeting, and how the company balances spending with its stated intent to streamline expenses while preparing for potential launches in related indications.